| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/14787210.4.5.743 |
| P698 | PubMed publication ID | 17140351 |
| P2093 | author name string | Zeina A Kanafani | |
| P2860 | cites work | Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus | Q24556635 |
| Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users | Q24675979 | ||
| Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects | Q33554391 | ||
| Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus | Q34077052 | ||
| In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp | Q34141027 | ||
| Tissue penetration of telavancin after intravenous administration in healthy subjects | Q34352132 | ||
| Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study | Q34509652 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Semi-synthetic glycopeptide antibacterials | Q35586461 | ||
| Glycopeptides in clinical development: pharmacological profile and clinical perspectives. | Q35879826 | ||
| Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria | Q36670352 | ||
| In vitro activity of TD-6424 against Staphylococcus aureus | Q40130630 | ||
| Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus | Q41814975 | ||
| Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters | Q41831644 | ||
| Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria | Q43553034 | ||
| Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria | Q44803993 | ||
| Endocarditis caused by Staphylococcus aureus with reduced susceptibility to vancomycin | Q44850137 | ||
| Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects | Q44938149 | ||
| Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). | Q45013095 | ||
| Telavancin: in vitro activity against staphylococci in a biofilm model | Q46561648 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 743-749 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Telavancin: a new lipoglycopeptide with multiple mechanisms of action | |
| P478 | volume | 4 |
| Q37465197 | Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management |
| Q37291338 | Current challenges in treating MRSA: what are the options? |
| Q26853465 | Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci |
| Q37077627 | Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections. |
| Q38522574 | Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections |
| Q39686295 | Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation |
| Q56387334 | To Market, To Market—2009 |
Search more.